FDA Releases Revised Guidance on Bioequivalence and Dissolution Testing for Buspirone Hydrochloride Tablets

Summary

The FDA has made a revised guidance for industry available, which includes new information on bioequivalence and dissolution testing for buspirone hydrochloride tablets, particularly in 15-milligram dosage forms, following the recent approval of these tablets.